Dergiler / GORM:Gynecology Obstetrics & Reproductive Medicine / 2019 / Cilt: 25 - Sayı: 2

Risk of Malignancy Index Has a Poor Sensitivity in Detecting Borderline Epithelial Tumors and Non-Epithelial Ovarian Tumors

Sayfa
101–106
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

İt has a high diagnostic performance in detecting invasive epithelial ovarian cancers, but it has a poor sensitivity in detecting borderline ovarian tumors and non-epithelial ovar- ian cancers.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVES: To evaluate diagnostic accuracy of "Risk Of Malignancy İndex-1" (RMI-1) for post- menopausal adnexal masses.
📊
Temel Bulgular & Veri:RMI-1 scores were calculated through the formula: [RMI= Ultrasound Scorex Menopause Score x Serum Ca-125 Level] and noted preoperatively by the same sonographer for each case. "Final histopathological diagnosis" was accepted as gold standard for benign-malignant categorical distribution.
💡
Sonuç & Katkı:İt has a high diagnostic performance in detecting invasive epithelial ovarian cancers, but it has a poor sensitivity in detecting borderline ovarian tumors and non-epithelial ovar- ian cancers.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

OBJECTIVES: To evaluate diagnostic accuracy of "Risk Of Malignancy İndex-1" (RMI-1) for post- menopausal adnexal masses. STUDY DESIGN: Fifty postmenopausal women who had undergone surgery because of adnexal masses were included in this prospective study. RMI-1 scores were calculated through the formula: [RMI= Ultrasound Scorex Menopause Score x Serum Ca-125 Level] and noted preoperatively by the same sonographer for each case. "Final histopathological diagnosis" was accepted as gold standard for benign-malignant categorical distribution. Borderline tumors were categorized in malignant tumor group. RESULTS: According to final histopathological results; 20 of the 50 patients had malignant adnexal masses. Twelve of them had invasive epithelial tumors. The remaining 8 patients had borderline epithelial tumors or non-epithelial ovarian cancers. When the RMI score ≥200 was accepted as a positive test result compatible with the literature; we calculated the sensitivity: 75%, specificity: 93%, positive predictive value: 88%, negative predictive value: 85% predicting malignant adnexal masses. All of the 12 patients with invasive epithelial tumors had RMI-1 scores higher than 200. Nevertheless, only 3 of the 8 patients with borderline epithelial tumors or non-epithelial ovarian cancers had RMI-1 scores higher than 200. We have found out that invasive epithelial tumors had higher USG Scores, Ca-125 Levels and RMI Scores when compared to borderline epithelial tumors and non-epithelial ovarian cancers and the difference was statistically significant. CONCLUSIONS: RMI-1 is a valuable and applicable method in the initial evaluation of postmenopausal patients with adnexal masses. İt has a high diagnostic performance in detecting invasive epithelial ovarian cancers, but it has a poor sensitivity in detecting borderline ovarian tumors and non-epithelial ovar- ian cancers.

🔖

Bu Makaleye Atıf Yap

DURMUŞ, Y., MEYDANLI, M. M. (2019). Risk of Malignancy Index Has a Poor Sensitivity in Detecting Borderline Epithelial Tumors and Non-Epithelial Ovarian Tumors. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 25 - Sayı: 2, 101–106. https://ajindex.com/articles/158886

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Hilger WS, Magrina JF, Magtibay PM. Laparoscopic management of the adnexal mass. Clin Obstet Gynecol. 2006;49(3):535-48. McGowan L. Patterns of care in carcinoma of the ovary. Cancer. 1993;71(2 Suppl):628-33.
  2. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248-59.
  3. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accu- rate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97(10):922-9.
  4. Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol. 1996;103(8):826-31.
  5. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol. 1999;93(3):448-52.
  6. Yamamoto Y, Yamada R, Oguri H, Maeda N, Fukaya T. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol. 2009;144(2):163-7.
  7. Van Gorp T, Veldman J, Van Calster B, Cadron I, Leunen K, Amant F, et al. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminat- ing benign from malignant adnexal masses. Eur J Cancer. 2012;48(11):1649-56.
  8. Valentin L, Jurkovic D, Van Calster B, Testa A, Van Holsbeke C, Bourne T, et al. Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol. 2009;34(3):345-54.
  9. Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB, Guerriero S, et al. Simple ultrasound rules to distin- guish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010;341:c6839. Timmerman D. The use of mathematical models to evaluate pelvic masses; can they beat an expert operator? Best Pract Res Clin Obstet Gynaecol. 2004;18(1):91-104. Ovarian cancer: recognition and initial management Clinical guideline [CG122] Published date: April 2011 https://www.nice.org.uk/guid